Form 4: Corvus Pharmaceuticals Executive Exercises Warrants, Increases Stake

William Benton Jones, SVP of Pharmaceutical Development at Corvus Pharmaceuticals, Inc., has exercised warrants to acquire 19,357 shares of common stock, increasing his direct beneficial ownership.

Summary

• William Benton Jones, the Senior Vice President of Pharmaceutical Development at Corvus Pharmaceuticals, Inc. (CRVS), reported a change in his beneficial ownership.
• On June 4, 2025, Mr. Jones exercised 19,357 warrants, which had an exercise price of $3.5 per share.
• As a result of the exercise, he acquired 19,357 shares of Corvus Pharmaceuticals' common stock.
• Following this transaction, Mr. Jones's direct beneficial ownership of common stock increased to 173,130 shares.
• The warrants exercised were originally issued at no additional consideration in connection with a subscription for shares of the Issuer's Common Stock at a price of $1.7312 per share.

Sentiment

Score: 7

Explanation: The exercise of warrants by a senior executive to increase their direct ownership is generally viewed as a positive signal, indicating confidence in the company's future performance.

Positives

• The exercise of warrants by a senior executive indicates confidence in the company's future prospects, as they are increasing their direct equity stake.
• An increase in insider ownership aligns the interests of management more closely with those of shareholders.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic outlook.

Management Comments

• William Benton Jones is identified as the SVP, Pharmaceutical Development.

Industry Context

Insider transactions, such as the exercise of warrants, are common occurrences in publicly traded companies, particularly in the biotechnology and pharmaceutical sectors where equity compensation is a significant component of executive remuneration. Such transactions can provide insights into management's perception of the company's value.

Related Party Transactions

• The transaction involves an officer of Corvus Pharmaceuticals, William Benton Jones, exercising warrants to acquire company stock, which is a common form of related party transaction in the context of executive compensation.

Stakeholder Impact

• Shareholders may view this increase in insider ownership as a positive indicator of management's belief in the company's value, potentially boosting investor confidence.

Key Dates

Keywords

Corvus Pharmaceuticals, CRVS, Form 4, Insider Transaction, Warrant Exercise, Beneficial Ownership, Executive Stock Ownership, Pharmaceutical Development